Microsoft word - cv_kh_long (20120619).docx

Curriculum Vitae - Dr. Kenneth John HARVEY
Contact Details
Medreach Pty. Ltd. 35a Mary St. Hawthorn, Victoria, 3122, Australia Telephone +61 3 9818 1910, Mobile: +61 4 1918 1910, Fax: +61 3 9818 1875 E-mail: k.harvey@medreach.com.au WWW: http://www.medreach.com.au Date of Birth
Marital Status
Married (Dr. Jenny Harvey); three adult children, all university graduates Current Position
 Adjunct Associate Professor, School of Public Health, La Trobe University (2012-) Special Interests
Therapeutic Goods Policy in Australia and other countries.  Quality of use (rational use) Information Technology  Decision support systems, especially e-prescribing and pathology Professional
 Member of the group of experts that devised the 1988 World Health Organization, Achievements
Ethical Criteria for Medicinal Drug Promotion  Founding member, and at various times author, Chair of Antibiotic Writing Group and Board Member of Therapeutic Guidelines Limited  Inaugural member of the PHARM committee that devised the Quality Use of Medicines (QUM) plank of Australian Medicinal Drug Policy  Awarded life membership of CHOICE (Australian Consumers' Association) for services to the consumer movement (also CHOICE 2012 Consumer champion)  Chair of the Governing Council of Health Action International, Asia Pacific (HAIAP). Previous Positions
 Resident Medical Officer, Port Moresby General Hospital, Territory of Papua & New  Pathology Registrar (Microbiology), The Prince Henry and Prince of Wales Hospital  Registrar in Medical Computing, New South Wales Health Department -The Prince Henry and Prince of Wales Hospital Group, Sydney (1973)  Trainee in Microbiology, Victorian Hospitals and Charities Commission  Medical Clinical Assistant, The Royal Melbourne Hospital, (1975-76)  Assistant Microbiologist, The Royal Melbourne Hospital (1976-84)  Director of Microbiology, The Royal Melbourne Hospital (1984-87)  External Drug Evaluator, Therapeutic Goods Administration (1985-91)  Senior Lecturer, School of Public Health, La Trobe University (1990-2005)  Honorary Senior Research Fellow, School of Information Technology & Mathematical Sciences, University of Ballarat (2001-2010)  Adjunct Senior Lecturer, School of Public Health, La Trobe University (2006-2011)  Australian Director, AusAID Philippines National Drug Policy Cooperation Project  Board Member, Therapeutic Guidelines Limited (1997-2004)  WHO Fellow: Rational Drug Use - Malaysia, Bangladesh, China (2000)  Council Member, Australian Consumers Association (2000-2005)  Consultant, Australian Health Insurance Commission (now Medicare Australia): Croatian and Jordan Pharmaceutical Reform (2003-2006)  Consultant, USAID-PHRplus: Jordan Pharmaceutical Reform (2005-06)  Consultant, Medicare Australia. An Economic & Equity Impact Review of Australian National Pharmaceutical System Models. Pharmaceutical Reform Working Group Steering Committee (2006) Curriculum Vitae - Dr. Kenneth John HARVEY
Qualifications
 MB BS (1967); FRCPA (1975); MASM (1984)  Medical Board of Australia Registration: MED0000996411 Overseas Experience
 Bangladesh, China, Croatia, Hong Kong, India, Indonesia, Jordan, Laos, Malaysia, Pakistan, Papua & New Guinea, Philippines, Singapore, Sri Lanka, Thailand, Vietnam. Committees (Now)
 Chair, Governing Council, Health Action International Asia Pacific (2010-)  Member, Policy Advisory Group, Australian Consumers Association (2006-)  Member, Therapeutic Goods Administration, Business Process Reform CEO Forum  Member, Australian Government Working Group on Regulatory Reform of Committees (Past)
 NH&MRC Medical Research Committee.  Therapeutic Goods Administration, Laboratory Advisory Committee.  Therapeutic Goods Advertising Code Council (Media Council of Australia).  Pharmaceutical Health and Rational Use of Medicines (PHARM) Committee, PHARM- Industry group and PHARM-Evaluation subcommittee of the Commonwealth Department of Community Services and Health.  WHO Expert Working Party that devised Ethical Criteria for Medicinal Drug Promotion  Organising Committee, International Conference on National Medicinal Drug Policies  International Coordinating Committee, People's Health Assembly 2000  Commonwealth Immunisation E-Handbook (8th edition) Working Party  General Practice Computer Group, Chronic Disease Management Working Group (2004-  National Tertiary Education Union (1990-2005)  Organising Committee, HAIAP, National Workshop on Rational Use of Antibiotics in  Co-Chair, IT14-2-1, Standards Australia Pharmacy Concept Terminology (2005-2008).  Member, Research and Development Working Group and Electronic Prescribing Study Guidance Group, Australian National Prescribing Service (2006-11)  Member, Australian Government Working Group on Promotion of Therapeutic Products  Member, Therapeutic Goods Administration Transparency Review Panel, (2010-2011)  Member, Scientific Program Committee, Asia Pacific Conference on National Medicines Membership of
 Australian Consumers Association (Life member). Organisations &
Professional Societies  Health Action International - Asia Pacific (HAIAP).
 Australian Skeptics (Victorian Branch)  Public Health Association of Australia. Relevant Publications Books
 PHARM Evaluation Sub-committee (Gilbert A, Brooks C, Corti B, Harvey K, Harvey R, James M, Murray M, Primrose J, Swift D.) Manual of Indicators to measure the effect of initiatives under the Quality Use of Medicine arm of the National Medicinal Drug Policy. Australian Government Publishing Service, Canberra 1995.  Harvey KJ (Chairman), Beavis M, Christiansen K, Collignon P, Currie B, Dartnell J, Ferguson J, Harkness J, Isaacs D, Khariwala B, Kucers A, Looke D, Spicer WJ, Tosolini FA, Turnidge J. Antibiotic Guidelines 10th Ed. Therapeutic Guidelines Ltd., Melbourne 1998 (and also involvement in the first edition and a number of previous editions).  Roughead EE, Gilbert AL, Primrose JG, Harvey KJ, Sansom LN. Report of the national indicators: Evaluating the quality use of medicines component of Australia's National Medicines Policy. Publications Production Unit, Commonwealth Department of Health and Aged Care, Canberra, 1999. Book chapters
 Harvey K, Murray M. Medicinal drug policy, in The Politics of Health, 2nd Ed., Gardner Curriculum Vitae - Dr. Kenneth John HARVEY
H (Ed) Churchill Livingstone, Melbourne, 1995, 238-283.  Harvey KJ. Drug Promotion, in Drugs in the Health Marketplace. Komesaroff PA, Wiltshire J. (Ed) Arena Publications, Melbourne 1997, 47-70.  Aroni R, de Boer R, Harvey K. The Viagra Affair. In Evidence-based Health Policy, Edited by Lin V & Gibson B. Oxford University Press, Melbourne 2003, 97-109.  Löfgren H, Harvey K. The Pharmaceutical Benefits Scheme, in Understanding the Australian Health Care System, 2nd Ed. Willis E, Reynolds L, Keleher H. (Ed) Churchill Livingstone Elsevier, Sydney, (publication date: early 2012).  Harvey K. Regulation of Complementary Medicines, in Perspectives on complementary and alternative medicines, Edited by Prof Ian Olver & Monica Robotin, Imperial College Press, Oct 2011. Editorials
 King K, Harvey K. MRSA Revisited (Editorial). Med J Aust 1985; 2: 88-89.  Darvall L, Harvey KJ Australian pharmaceutical advertising: a critique (Editorial). Med J  Harvey K. Quality assurance of therapeutic products and practice (Editorial). Med J Aust  Harvey K, Rogers S, Roughead L. Initiatives to improve antibiotic use (Editorial). Aust  Harvey K. Controlling complementary medicine claims (Editorial). Aust Prescr 2008; 31:  Harvey KJ, Day RO, Campbell WG, Lipworth L. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration? MJA Rapid Online Publication — 6 May 2011. Articles in refereed journals
 Harvey KJ, Smith DD. Antimicrobial sensitivity patterns as a guide to the domiciliary treatment of urinary tract infections. Med J Aust 1972; 1: 177-8.  Harvey KJ. Antibacterial activity in urine. Med J Aust 1972; 1: 1072-4.  Bell SM, Harvey KJ, Smith DD Double-blind trial comparing trimethoprim- sulphamethoxazole (Bactrim) with ampicillin in treating urinary infections. Med J Aust 1972; 1: 442.  Harvey KJ, Were M, Heys, Wendy, Smith DD. A time-shared computer system for data processing in bacteriology. Med J Aust 1972; 2: 1076.  Murnaghan GF, Tynan AP, Farnsworth RH, Harvey K. Chronic prostatitis--an Australian  Harvey K, Bishop L, Silver D, Jones T. A case of chancroid. Med J Aust 1977; 1:956-  Harvey K, Schuck S. Acinetobacter septicaemia following prolonged intravenous  Harvey KJ, Miles H, Hurse A, Carson M. In-vitro activity of erythromycin against anaerobic microorganisms. Med J Aust 1981; 1: 474-475.  Harvey K, Pavillard R. Methicillin resistance in Staphylococcus aureus with particular reference to Victorian strains. Med J Aust 1982 May 29; 465-7.  Pavillard R, Harvey K, Douglas D, Hewstone A, Andrew J, Collopy B, Asche V, Carson P, Davidson A, Gilbert G, Spicer J, Tosolini F. Epidemic of hospital-acquired infection due to methicillin-resistant Staphylococcus aureus in major Victorian hospitals. Med J Aust 1982; 1: 451-454.  Harvey K. Promotion of newer antimicrobial agents. Med J Aust 1983; 1: 27-8;  Harvey K, Stewart R, Hemming M, et al. Use of antibiotic agents in a large teaching hospital. The impact of Antibiotic Guidelines. Med J Aust 1983; 2: 217-2.  Harvey KJ, Stewart R, Hemming M, Naismith N, Moulds RF. Educational antibiotic  Avorn J, Harvey K, Soumerai SB, et al. Information and education as determinants of antibiotic use: Report of Task Force 5. Rev Infect Dis 1987; Suppl 3: S286-96.  Graves SR, Rosengren NJ, Kennelly-Merrit SA, Harvey KJ, Thornton IW. Antibiotic- resistance patterns and relative concentrations of bacteria (gram-negative rods) from ash deposits of various ages on the Krakatau islands. Philos Trans R Soc Lond B Biol Sci 1988; 322: 327-37. Curriculum Vitae - Dr. Kenneth John HARVEY
 Landgren FT, Harvey KJ, Mashford ML, et al. Changing antibiotic prescribing by educational marketing. Med J Aust 1988; 149: 595-9.  Harvey KJ. Antibiotic use in Australia. Aust Presc 1988; 11: 74-77.  Harvey K. Australia: Pharmaceutical Benefits Scheme. Lancet 1991; 337: 418-419.  De Santis G, Harvey KJ, Howard D, et al. Improving the quality of antibiotic prescriptions in general practice. The role of educational intervention. Med J Aust 1994; 1: 502-5.  Williams D, Chiu E, Harvey K. Does admission to a hospital geriatric psychiatry programme improve benzodiazepine and other drug use? Int J Geriatr Psychiat 1994; 9: 501-505.  Roughead EE, Gilbert AL, Harvey KJ. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? Int J Health Serv 1998; 28: 269-279.  Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust NZ J Med 1998; 28: 306-310.  Nolan AM, Norquay CA, Dartnell JGA, Harvey KJ. Electronic prescribing and computer-assisted decision support systems. MJA 1999; 171: 541-543.  Harvey K. Medication management 2000: e-Scripts, e-Promotion. e-Health? Health  Harvey Ken. Australian E-Health Policy: Once was Rational? Health Issues 2001: 67; 11-  Roughead EE, Monteith GR, Harvey KJ and Tett SE. Evaluating Australia's National Medicines Policy using Geographical Mapping. Internal Medicine Journal. 2002: 3; 66-72.  Phanouvong S, Barraclough S, Harvey K. Improving primary health care in Thailand: The role of the National Medicinal Drug Policy. Aust J Primary Health 2002: 8; 24-30.  Harvey K, Dartnell J, Hemming M. Improving antibiotic use: 25 years of antibiotic guidelines and related initiatives. Commun Dis Intell 2003; 27 Suppl: S9–S11.  Lewis B, Harvey K, Dartnell J, Shepheard J. Modelling and encoding Therapeutic Guidelines: applying ICD-10-AM and European Article Number codes. Health Information Management 2004; 32: 51-58.  Harvey K. Free Trade and the Cost of Medicines. Access 2004: 6; 19-24.  Harvey KJ, Faunce TA Lokuge B, Drahos P. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme? MJA 2004; 181 256-259.  Harvey K, Kalanj K and Stevanovi R. Croatian Pharmaceutical Sector Reform Project: Rational Drug Use. CMJ 2004; 45: 611-619.  Harvey K. Patents, pills and politics: the Australia–United States Free Trade Agreement and the Pharmaceutical Benefits Scheme. Aust Health Rev 2004; 28 (2): 218-226.  Harvey KJ. The Pharmaceutical Benefits Scheme 2003–2004. Australia and New  Harvey KJ, Vitry AI, Roughead E, et al. Pharmaceutical advertising in prescribing software: an analysis. MJA 2005; 183: 75-79.  Bader R, Mawajdeh S, Harvey K. Workshop boosts rational use activities in Jordan. WHO Essential Drugs Monitor 2005; 34: 22-23.  Zhang Y, Harvey KJ. Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines. Australia and New Zealand Health Policy 2006; 3 :5-17.  Harvey K. Pharmaceutical Advertisements in Prescribing Software: What Should be  Faunce TA, Lofgren H, Harvey K, Johnston K. Tendering for Low Cost Generics in Australia. Health Issues, 2006; Number 87: 26-29.  Harvey K. Changes in Pharmaceutical Policy over the last 20 Years. Health Issues 2006;  Harvey KJ, Harris AH, Bulfone L. The National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007: reform or fracture? MJA 2007; 187 (4): 206-207.  Harvey KJ, Korczak VS, Marron LJ, Newgreen DB. Commercialism, choice and consumer protection: regulation of complementary medicines in Australia. MJA 2008; Curriculum Vitae - Dr. Kenneth John HARVEY
 Harvey K. Does CM need reform? J Comp Med 2008; 7(3): 37.  Harvey K. Australian Complementary Medicine Regulation: Time for Reform! Health  Harvey K. A review of proposals to reform the regulation of complementary medicines.  Sweidan M, Williamson M, Reeve JF, Harvey KJ O'Neill JA, Schattner O, Snowdon T. Identification of features of electronic prescribing systems to support quality and safety in primary care using a modified Delphi process. BMC Medical Informatics and Decision Making 2010; 10:21.  Harvey K. Alternative treatments for impotence. Diabetes Management Journal 2010; 32:  Harvey K, Stough C. Caution with complementaries for cognitive impairment. Aust  Sweidan M, Williamson M, Reeve JF, Harvey K, O'Neill JA, Schattner P, Snowdon T. Evaluation of features to support safety and quality in general practice clinical software. BMC Medical Informatics and Decision Making 2011, 11:27.  Harvey K. “I want to consume this product; should public health experts stop me?” — Commissioned reports (1995-)
 Harvey K, Clark R. A Mechanism for the Development, Implementation and Evaluation of Evidence-Based, Best-Practice Clinical Guidelines to Facilitate Quality Use of Pathology Tests. The Quality Use of Pathology Committee (QUPC), 2002.  Harvey K. A Process for Developing Evidence Based Treatment Guidelines. Report 6.4, Reform of the Croatian Pharmaceutical Sector Project, Ministry of Health of the Republic of Croatia & Australian Health Insurance Commission, 2003.  Victorian Hospitals Electronic Prescribing and Decision Support Group (Harvey K, Editor). Electronic Medication Management. Victorian Drug Usage Advisory Committee, Melbourne, 2003.  Harvey K. Linking Therapeutic Guidelines with the Primary Health Care Information Technology Project. Report 6.5 Reform of the Croatian Pharmaceutical Sector Project, Ministry of Health of the Republic of Croatia & Australian Health Insurance Commission, 2003.  Harvey K. Guidelines for Assessing Future Projects under the Quality Use of Pathology (QUP) Program. Commonwealth Department of Health & Aging, 2004.  Harvey K, McCauley V, MacIsaac P, Lewis B. Refinement of the HL7 Australia EDS Work plan: A report for the Australian Health Information Council Electronic Decision Support Steering Committee. HL7 Australia 2004.  Harvey K. Deliverable 5: Methodology for the Development of Standard Treatment Guidelines. Jordan Health Sector Reform Project, Jordan Food & Drug Administration & Australian Health Insurance Commission, 2004.  Harvey K. Deliverable 9: Study of Prescribing Practices. Jordan Health Sector Reform Project, Jordan Food & Drug Administration & Australian Health Insurance Commission, 2004.  Harvey K. Critical assessment of Jordan RDU EDL within the International context.  Medicare Australia Consultancy. An Economic & Equity Impact Review of National Pharmaceutical System Models. Pharmaceutical Reform Working Group Steering Committee, 2006. Conference proceedings &/or presentations (1995-)
 Harvey, K. The National Manual of QUM Indicators. Pharmaceutical Education Program, 1995 Work in Progress Conference Proceedings, Commonwealth Department of Health and Family Services, 1996, 14.  Harvey, K. The way forward. Pharmaceutical Education Program, 1995 Work in Progress Conference Proceedings, Commonwealth Department of Health and Family Services, 1996, 36.  Harvey K, Nolan A, Dartnell J. Deconstructing Therapeutic Guidelines: from printed books to computerised decision support systems. ASCEPT conference proceedings, Curriculum Vitae - Dr. Kenneth John HARVEY
 Norquay C, Dartnell J, Phanouvong S, Harvey K, Hemming M. Moving from the known to the unknown: From print to electronic Therapeutic Guidelines. ASCEPT conference proceedings, Hobart, 1998.  McKinnon R, Harvey K. Containing Vancomycin-resistant Enterococci: Strategies for Victoria. (Conference Report) Victorian Drug Usage Advisory Committee, Melbourne, 1999  Harvey K. Teledisaster? A case study of the recently abandoned Commonwealth Therapeutic Health Information Project. Australian & New Zealand Health Services Research Conference, 1999.  Harvey K. From optimising antibiotic use to involvement in national medicinal drug and health IT policy: issues relevant to decision support. General Practice Computing Group Electronic Decision Support Workshop, Canberra, 1999.  Harvey K. Exporting Australian E-Health Expertise. AIC Worldwide Conferences E-  Harvey K. Therapeutic Knowledge Databases. SPIRT Pharmaceutical Decision Support  Harvey K. SPIRT Pharmaceutical Decision Support Workshop. School of Information Technology & Mathematical Sciences, University of Ballarat, March 2000.  Harvey K. Medication Management 2000: e-Promotion, e-Scripts, e-Health? 2nd International Primary Health Care Conference, Melbourne April 2000  Harvey K. Pharmaceutical Decision Support Systems. International Workshop on Enterprise Networking and Computing in HealthCare Industry (Healthcom 2000), Sydney, April 2000.  Harvey K. The Doctors Assistant: Decision Support. Mornington Peninsular Division of General Practice, IT-Expo, 13-14th May 2000  Harvey K. Information for Decision Support: Therapeutics. NHIMAC National Health  Harvey K. Pharmaceutical Decision Support. Victorian Society of Hospital pharmacists  Harvey K. Tensions in Australian Medicinal Drug Policy: The Pharmaceutical Benefits Advisory Committee Controversy. 2nd bilateral research conference, Ateneo de Manila University – La Trobe University, April 18-20, 2001  Harvey K. National Antibiotic Summit, Sydney. Workshop discussant, 30 to 31 May,  Harvey K, “Experts at Risk: The Role of Advocacy and Science in the Development of Public Health Policy: The PBAC controversy”. Public Health Association of Australia, ACT Branch, University House, Australian National University, 18 June 2001.  Harvey K. Recent controversies surrounding the Australian Pharmaceutical Benefits Scheme (PBS) IIR s E-PHARMA Conference, Meridian Hotel, Sydney, 27- 29 June 2001.  Harvey K. How TNCs shape Consumer Culture: The Case of Pharmaceuticals. Asia Pacific Research Network (APRN) Conference - Corporate Power or Peoples Power: TNCs and Globalization, Sydney, 27 September 2001  Harvey K. Risky Business: Improving Antibiotic Use in Australia. Keynote Address. Victorian Infection Control Practitioners Association (VICPA) Conference, 15 November 2001.  Harvey K. Pharmaceutical Decision Support. E-Health Workshop for Health Professionals. La Trobe University, 23 November 2001.  Harvey K. TRIPS & Pharmaceuticals in a public forum on GATS, TRIPS, Globalisation and Public Health. The Victorian Public Health Association and VicHealth, 14 March 2002.  Harvey K. Pharmaceutical Decision Support, GnuMed conference, Lismore, NSW, 25-27  Harvey KJ. Meet a therapeutic guideline activist – Meet the Expert Session, Improving Medication Management Workshop, Department of Human Services, Melbourne, November 2002  Harvey KJ. Patient safety and clinical risk management: the challenge of implementing Curriculum Vitae - Dr. Kenneth John HARVEY
computerised prescribing and decision support systems. Key Note Address. Society of Hospital Pharmacists of Australia Victorian State Branch Conference, Bendigo, November 2002.  Harvey KJ, Zhang Y, Antibiotic resistance. Infection Control Seminar, Gippsland Regional Infection Control Group, La Trobe Valley Hospital, Tralagon, November 2002.  Harvey K. Resistance to Antibiotics. ABC Radio National Perspective, Thursday 12  Harvey K. Meet the Expert (Therapeutic Guidelines). Improving Medication Management Workshop. Quality and Care Continuity Branch Metropolitan Health and Aged Care Division, Department of Human Services, November 2002.  Harvey K. Update on Decision Support and Guideline representation from HL7, Cleveland. Austin Hospital Informatics – Work In Progress Seminar, June 2003.  Harvey K. Saving the Pharmaceutical Benefits System. Fabians Society & Doctors Reform Society, Trades Hall, Melbourne, June 2003.  Harvey K. Decision Support Tutorial (invited) Health Informatics Conference, Sydney,  Harvey K (panel member). The Future of Open Knowledge in General Practice. GPCG  Harvey K. The Need for Decisions Support Standards - a User Perspective. HL7 Australia Decision Support Conference, Sydney, August 2003.  Harvey K. Antibiotic resistance. Infection Control Seminar, Gippsland Regional Infection  Harvey K. Saving the Pharmaceutical Benefits System. Health Economic Unit, Monash  Harvey K. (Co-Chair) Workshop background. HL7 Australia & New Zealand, Clinical Decision Support Workshop, December 2003.  Harvey K. The Croatian Pharmaceutical Reform Project. School of Public Health  Harvey K. The FTA and the PBS: Public Health & Consumer Concerns. Fabians and Doctors Reform Society, Melbourne, July 2004.  Harvey K. International experience with rational drug use. Jordan Food & Drug Administration, Rational drug use workshop, Marriott Hotel, Dead Sea, September, 2004.
 Harvey K. Impact of E-Prescribing on Antibiotic Use in Australia. American Society of Microbiology Annual Meeting on Infectious Diseases (ICAAC 2004), Washington USA, October 2004.  Harvey K. The Australian Pharmaceutical Benefits Scheme 1994-2004. United States Pharmacopeia, Rockville, USA, November 2004.  Harvey K. Will the AUSFTA undermine the PBS? Society of Hospital Pharmacists of Australia, Victorian Branch, November 2004.  Harvey K. Cost containment in Pharmaceutical Benefit Scheme, Australia at International Conference on Cost Containment in National Health Insurance System, Chaingmai, Thailand, 25-25 February 2005.  Harvey K. Pharmaceutical promotion in prescribing software: an analysis. La Trobe University, School of Public Health Research Seminar, March 2, 2005.  Harvey K. The PBS and Quality Use of Medicines, Medication Management Review Workshop, La Trobe University, Bendigo, March 19, 2005.  Harvey K. Free markets and medical software. Fabian Society, Victorian Trades Hall,  Harvey K. Promotional practices: the need for action. Asia Health Forum, Universiti  Harvey K. Is the PBS sustainable? Current problems; possible solutions? ALP Hawthorn Branch, May 4, 2005; also Australian College of Pharmacy, Victorian Fellows Dinner, May 19, 2005.  Harvey K. Profit driven research: The problems. Cabrini Hospital Human Research Ethics Committee Seminar, Who Profits from Research? Malvern, June 2, 2005.  Harvey K, Critical assessment of Jordan’s RDU & EDL within the International context. National Workshop on Progress in Jordan National Drug Policy / Towards Implementing an Essential Drug List, Amman, Jordan, July 2, 2005. Curriculum Vitae - Dr. Kenneth John HARVEY
 Harvey KJ (Session Moderator & Lead Presenter). Pharmaceutical promotion in medical software. Health Informatics Conference August 2, 2005.  Harvey K. Does pharmaceutical marketing unbalance the PBS? 3rd Future of the PBS  Harvey K. Free Markets and Medical Software. Monash Department of Epidemiology and Preventative Medicine Research Seminar, September 21, 2005.  Harvey K. From Victorian State Antibiotic Guidelines to Australian Quality Use of Medicines Policy &The Australian Pharmaceutical Benefits Scheme: Ensuring equitable access to necessary medicines for rich and poor. 2nd National Workshop on Rational Use of Antibiotics in China, Beijing, November 28-30, 2005.  Harvey K. Curbing Pharmaceutical Promotion: (fighting the commercialisation of health). HAIAP Seminar, GK, Dhaka, Bangladesh, April 10-12, 2006.  Harvey K. The reporting of medicines in the media: research findings. National Prescribing Service Seminar for Health and Medical Writers, Sydney, May 3, Canberra, May 31, 2006.  Harvey K. Electronic medication management. 2nd Annual eHealth Conference, 31st  Harvey K, Sweet G, Horsfall B. Evidence vs hype: informing better prescribing. National Prescribing Service Dandenong - District Division of General Practice, May 6, 2006, June 20, 2006; Greater South Eastern Division of General Practice, August 30, September 4, 6, 28, 2006.  Harvey K. Australian Private Health Insurance: Inclusive and Equitable? International Society for Equity in Health Meeting, Adelaide September 11, 2006.  Harvey K. Drug Formularies and Rational Drug Use; The Role of Pharmacy & Therapeutic Committees; Drug Evaluation. Jordan National Drug Formulary Dissemination and Implementation Strategy Workshop & PTC Training Workshops, Amman, Jordan, September 18-20, 2006  Harvey K. Complementary therapies: What every consumer with a chronic illness should know. Chronic Illness Alliance AGM, 13 December 2006.  Harvey K. Private Health Insurance Controversies. U3A Hawthorn Summer School, 12 January 2007, U3A Stonnington, 28 March, 2007.  Harvey K. A Sustainable Pharmaceutical Benefits Scheme. U3A Hawthorn Summer School, 19 January 2007, U3A Stonnington, 4 April, 2007.  Harvey K. Electronic Health Records. U3A Hawthorn Summer School, 26 January 2007,  Harvey K. The 4th Annual Future of the PBS Conference. Conference Chair & Changes in health: a snapshot on prevalent therapeutic drug requirements - Informa Pty. Ltd. 30 April, 2007.  Harvey K. Antibiotic resistance and antibiotic use. Monash Medical School. R1, May 18,  Harvey K. Complementary and alternative therapies. U3A Manningham, July 23, 2007.  Harvey K, Korczak V, Marron L, Newgreen D. Complementary Medicine: Commercialism, choice and consumer protection. School of Public Health Research Seminar, La Trobe University, 15 August, 2007.  Harvey K. Debating Globalisation: Medicinal Drug Policy. Menzies College, La Trobe  Harvey K. The Crises in Health Funding – Sustainability of the PBS. Yarra Valley U3A, La Trobe University, September 27, 2007.  Harvey K. Medicinal Drug Policy. Flinders University, Adelaide, October 19, 2007.  Harvey K. Complementary Medicine: Commercialism, choice and consumer protection. U3A Hawthorn Summer School, January 16, 2008.  Harvey K. Transparency and the PBS. 5th Annual Future of the PBS Conference,  Harvey K. Complementary Medicine Reform, National Medicines Symposium, May 16,  Harvey K. Complementary Medicine Reform. Blackmores, Sydney, June 17, 2008.  Harvey K. Complementary Medicine Reform. St. Vincent's Hospital, Sydney, August 15, Curriculum Vitae - Dr. Kenneth John HARVEY
 Harvey K. Australia-US Free Trade Agreement and the PBS. HAIAP, Bangkok, August  Harvey K. E-Health, Patients and Ethics. HIC08, Melbourne, Sept 1, 2008.  Harvey K. Regulation of Complementary Medicines, MCHR Seminar, Oct 22, 2008.  Harvey K. Perceptions of the pharmaceutical industry. GSK Executive & staff seminars,  Harvey K. Complementary Medicine Reform. Therapeutic Expert Advisory Group,  Harvey K. Antibiotic resistance and antibiotic use. Monash Medical School, May 22,  Harvey K. Perceptions of the pharmaceutical industry. Pharma Phact, University of  Harvey K. Educational initiatives to improve rational drug use. HAIAP, Negombo, Sri  Harvey K. Antibiotic resistance and rational antibiotic use. VMPF Country education Program, Sale, Aug 20; Stawell, Sept 7, 2009  Harvey K. Controlling unethical promotion: has the Australian approach worked? Health Skepticism Meeting, Adelaide, Sept 24, 2009  Harvey K. Rational Drug Use in Australia: the Role of the National Prescribing Service.  Harvey K. Complementary Medicines: The need for reform. Dromana Skeptics, Oct 22,  Harvey K. Perceptions of the pharmaceutical industry. Sanofi-aventis seminar, Nov 5,  Harvey K. Antibiotic resistance and rational antibiotic use. VMPF Country education Program, Warrnambool Feb 25, Colac April 14, Albury June 25, Leongatha , Sept 15 2010  Harvey K. Shonky Medical Devices: a preliminary report. U3A Hawthorn, March 12,  Harvey K. Complementary Medicines Regulation. Swinburne University, April 22, 2010-  Harvey K. Why the push for a single code system? ASMI, Sydney, May 4, 2010  Harvey K. Antibiotic resistance and rational antibiotic use. Monash Medical School, May  Harvey K. Health Activism in Australia: Pharmaceutical Promotion. HAI Europe /  Harvey K. Critical Appraisal of Drug Company Promotional Techniques. PAC10,  Harvey K. Great debate: Pharmacists Should Only Sell Evidence Based Products.  Harvey K. International Relations and Pharmaceuticals. La Trobe University, International Health Relations, February 19, 2011.  Harvey K. Global Health and Pharmaceuticals. Monash University, March 18, 2011.  Harvey K. Advertising issues. TGA Transparency Review Panel Meeting, March 23,  Harvey K. Current regulatory landscape. DTCA Workshop, Sydney, April 20, 2011.  Harvey K. Your TGA? Skeptics Victoria, La Notte, June 12, 2011  Harvey K. War stories of a health activist. ANZAAS Science Talk, July 20, 2011.  Harvey K. SensaSlim, SLAPP writs, the CRP, TGA and the ACCC. Mordi Skeptics.  Harvey K. Complementary Medicine Reform and Workshop: Evaluating Evidence: Submitting Complaints. SA Adelaide. August 7, 2011.  Harvey K. My perspective on recent reviews. Medicines, Health Technologies and Reform Workshop, Canberra August 29, 2011.  Harvey K. Health Activism: The SensaSlim Saga. HAIAP, Penang, Malaysia, Sept 5,  Harvey K. Health Activism: SensaSlim, Civil Society and the TGA. USM DSAP Curriculum Vitae - Dr. Kenneth John HARVEY
Seminar, Penang, Malaysia, Sept 9, 2011.  Harvey K. SensaSlim Update. Skeptics Groups of Victoria, La Notte, Jan 29, 2012.  Harvey K. The Regulation of Complementary Medicines: a consumer perspective. Centre for Human Psychopharmacology, Swinburne University, Feb 6, 2012.  Harvey K. Evidence Based Complementary Medicines. Pharmaceutical Society of Aus- tralia Continuing Education, Monash Medical Centre, Feb 8, 2012; Balwyn High School, Mar 21, 2012.  Harvey K. International Relations and Pharmaceuticals. La Trobe University City cam-  Harvey K. TGA Reform: the Impact of Civil Society Activism. Victorian Skeptics, La  Harvey K. Lifting the evidence base: CMQUM. APP 2012, Sofitel Gold Coast, March  Harvey K. Regulatory Reform of Complementary Medicines. Monash University Phar-  Harvey K, Ratten R, Rea J. Flamed or Defamed: Reducing the Risk for Academics Con- tributing to Online Debates. La Trobe University, School of Public Health, April 2, 2012.
 Harvey K. Improving the Evidence Base for Complementary Medicines. NPS Board  Harvey K, Basser S, Golden I. Public Lecture: Medicine and Homeopathy. University of  Harvey K. Kaur S (Convenors). Workshop 8, Advertising and promotion. Australian Pa- cific Conference National Medicines Policy, May 26-29, 2012.  Harvey K. Perceptions of the pharmaceutical industry. Pfizer staff seminar, May 30, 2012 Harvey K. Improving pharmaceutical promotion in Australia. NPS NMS and APCNMP Other printed publications
 Pilbeam M, Harvey K. Antibiotic advice (letter). Aust Fam Physician 1987; 4: 369-370.  Harvey K. PBS charges. (letter) Med J Aust 1991;154: 364-365.  Harvey K. What influences prescribing--scientific articles or promotional pressure?  Harvey K. Medicines Information on the net. MediScene Newsletter 1998; 7: 3-4.  Harvey K, Patient records for sale. The Australian Health Consumer 2001; 2:42.  Harvey K. Exploring Electronic Medication Management. INRUD News 2003: 13; 35-  Harvey K. Free Trade and the Cost of Medicines. Access 2004: 6; 19-24.  Schattner P, Harvey K. Computers in General Practice: Module 4, Electronic Resources.  Harvey K. Rebate is a prescription for lazy healthcare. The Canberra Times. 1 March  Harvey K. Injunction impedes independent information (letter). Aust Prescr 2007; 30: 33. http://www.australianprescriber.com/magazine/30/2/32/4/  Pollard NA || Santoro A || Kotsirilos V || Masters CS || Harvey KJ, Korczak VS, Marron LJ and Newgreen DB. Commercialism, choice and consumer protection: regulation of complementary medicines in Australia [letters]. Med J Aust 2008; 189 (1): 50-53. http://www.mja.com.au/public/issues/189_01_070708/letters_070708_fm-2.html  Harvey K. Complementary Medicine: Handle with Care. Issues 2008; 84:7-9.  Harvey J. Homeopathy costs us all. Australasian Science 2010; 31(5): 38. Publication in other
 ABC Radio National Perspective, Antibiotic Resistance, 12/12/2002. Transcript available at: http://www.abc.net.au/rn/talks/perspective/stories/s745380.htm  ABC Radio Australia Talks, July 23, 2008. August 13, 2008 http://www.abc.net.au/rn/australiatalks/stories/2008/2311121.htm  ABC Radio Australia Talks, Complementary medicine. August 13, 2008 http://www.abc.net.au/rn/australiatalks/stories/2008/2332821.htm  ABC Radio Life Matters, Headaches: what’s new? Nov 22, 2010 Curriculum Vitae - Dr. Kenneth John HARVEY
 http://www.abc.net.au/rn/lifematters/stories/2010/3061507.htm  ABC Health Report, Regulation of Complementary Medicines. May 16, 2011  http://www.abc.net.au/rn/healthreport/stories/2011/3215960.htm
Film
 ABC and BBC Horizon program. The Microbe Masters the Mould. A 50 minute scientific documentary film on antibiotic resistance, 1986.  WHO Drug Action Program. Prescribing rationally, not fashionably. An Australian video produced in association with Dr. Frances Black (RACGP-FMP Educator). An Indian version, Push, Promote or Educate? also produced in association with Prof. CH Shasindran and Prof. KR Sethuraman, of the Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India, 1990.  Norquay C, Dartnell J, Phanouvong S, Harvey K. (electronic conversion authors) E- Antibiotic Guidelines (HTML Help format) 10th Ed. 1999 Therapeutic Guidelines Ltd., Melbourne 1999. World Wide Web (WWW)
 Coulthart R, Harvey K, et al. ‘The Doctor’s Gravy Train’, Nine Network Australia Sunday Program, August 5, 2001 http://news.ninemsn.com.au/sunday/cover_stories/article_896.asp  Harvey K, The Pharmaceutical Benefits Scheme (Nov 2, 2001) Digest http://www.australianreview.net/digest/2001/11/harvey.html  Harvey K, Symposium: The 2002-03 Federal Budget - Securing the future of the PBS? (June 3 2002) Digest http://www.australianreview.net/digest/2002/06/harvey.html  Harvey K. Pharmaceutical benefits and free trade: trouble ahead for subsidised medicines in Australia? (March 19, 2004) Digest http://www.australianreview.net/digest/2004/03/harvey.html  Harvey K. Private Health Insurance: Where are we now and where should we be going? 22 February 2006. http://cpd.org.au/article/private-health-insurance%3A-where-are-we-now-and-where-should-we-be-going%3F  Harvey K. The Sale of Medibank Private.1 March 2006. http://cpd.org.au/article/sale-  Harvey K. Drug companies' free lunches have expensive side-effects, 4 August, 2006. http://cpd.org.au/article/drug-companies%2526%2523039%3B-free-lunches-have-expensive-side-effects  Harvey K. Policy Change Needed for Complementary Medicines. Insight, August 2008. http://cpd.org.au/article/policy-change-needed-complementary-medicines  Harvey K. et al. Doctors and drugs. SBS Insight 26 May, 2009. http://news.sbs.com.au/insight/episode/index/id  Harvey K. Doctors and drugmakers: are new laws the answer? MJA Insight. 13 September 2010. http://www.mjainsight.com.au/view?post=dr-ken-harvey-doctors-and-drugmakers-are-new-laws-the-answer&post_id=571&cat=comment  Harvey K. Our world depends on investment in antibiotics. MJA Insight. 27 September 2010. http://www.mjainsight.com.au/view?post=ken-harvey-our-world-depends-on-investment-in-antibiotics&post_id=856&cat=comment  Harvey K. The risks from vague medicine labels. MJA Insight. 7 March 2011. http://www.mjainsight.com.au/view?post=ken-harvey-the-risks-from-vague-medicine-labels&post_id=3572&cat=comment  Harvey K. SensaSlim and me: how criticism of a weight-loss spray landed me in court. The Conversation, 20 June, 2011. http://theconversation.edu.au/sensaslim-and-me-how-criticism-of-a-weight-loss-spray-landed-me-in-court-1911  Harvey K. Some reaction to the transparency review of the TGA. Croaky, July 20, 2011. http://blogs.crikey.com.au/croakey/2011/07/20/some-reaction-to-the-transparency-review-of-the-tga  Harvey K. Surviving the SensaSlim saga. MJA Insight. 29 August 2011. http://www.mjainsight.com.au/view?post=ken-harvey-surviving-the-sensaslim-saga&post_id=5991&cat=comment  Harvey K. The problem with patents and chronic disease ABC Radio Saturday Extra. 24 September 2011. http://www.abc.net.au/rn/saturdayextra/stories/2011/3324321.htm Curriculum Vitae - Dr. Kenneth John HARVEY
 Harvey K. Pharmacies to push supplements as ‘fries and Coke’ to prescriptions. The Conversation. 27 September 2011. http://theconversation.edu.au/pharmacies-to-push-supplements-as-fries-and-coke-to-prescriptions-3578  Harvey K. Pills deal comes with its own ills [Opinion]. SMH. Sept 28, 2011. http://www.smh.com.au/opinion/society-and-culture/pills-deal-comes-with-its-own-ills-20110927-1kvb9.html  Collett M, Harvey K. Controversial Blackmores pharmacy deal withdrawn. ABC News. Oct 6, 2011. http://www.abc.net.au/news/2011-10-06/controversial-blackmores-pharmacy-deal-withdrawn/3317960?section=business  Harvey K. Companion deal raises CM evidence issues. Oct 17. 2011. http://www.medicalobserver.com.au/news/companion-deal-raises-cm-evidence–issues  Harvey K. One wrong foot after another: the ethics of the Pharmacy Guild’s deals. Oct 20, 2011. http://theconversation.edu.au/one-wrong-foot-after-another-the-ethics-of-the-pharmacy-guilds-deals-3939  Harvey K. TGA all bark no bite as Labor botches response to a series of reviews. Dec 8, 2011. http://theconversation.edu.au/tga-all-bark-no-bite-as-labor-botches-response-to-a-series-of-reviews-4640  Harvey K, Mares P. ABC Radio National Interest. Health watchdog gets a few more teeth, but still lacks bite. Dec 9, 2011. http://www.abc.net.au/radionational/programs/nationalinterest/health-watchdog-gets-a-few-more-teeth2c-but-still-lacks-bite/3723236  Harvey K. New weight-loss claims show TGA reforms aren’t working. The Conversation, Feb 23, 2012. http://theconversation.edu.au/new-weight-loss-claims-show-tga-reforms-arent-working-5526  Moses G, Cheney T, Harvey K, Myers S, Tiralongo E, Wardle J. Complementary Medicines: The Best Advice. Rural Health Education Foundation, Feb 28, 2012. http://www.rhef.com.au/programs/program-1/?program_id=580  Harvey K. CM evidence is testing. MJA Insight, Mar 26, 2012. http://www.mjainsight.com.au/view?post=Ken+Harvey%3A+CM+evidence+is+testing&post_id=8550  Brennan L, Harvey K. Ethics of accepting suppliers' gifts in the business v medical world. The Conversation, April 12, 2012. http://theconversation.edu.au/ethics-of-accepting-suppliers-gifts-in-the-business-v-medical-world-3968  Harvey K. Consumer input in Medicines Australia’s code of conduct review. The Conversation, 16 April, 2012. http://theconversation.edu.au/consumer-input-in-medicines-australias-code-of-conduct-review-6370  Harvey K. Swisse Vitamins highlights the failure of industry self-regulation. The Conversation, 19 April 2012. http://theconversation.edu.au/swisse-vitamins-highlights-the-failure-of-industry-self-regulation-6535  Harvey K. Companies tussle over market share for anti-cholesterol drug Lipitor® and its generic equal. The Conversation, May 18, 2012. https://theconversation.edu.au/companies-tussle-over-market-share-for-anti-cholesterol-drug-lipitor-and-its-generic-equal-7088

Source: http://www.medreach.com.au/wp-content/uploads/2012/06/CV_KH_Long-20120619.pdf

19.doc

Fit Measurement: How to Distinguish Between Fit and Notes for Brainstorming Session prepared by Pnina Soffer Discussion mission 1. To characterize approaches to fit assessment and identification. 2. To characterize fit maintenance triggers and policies, and factors that should Motivation Business processes may change frequently, as the business environment is dynamic and constantly e

Max890e.pdf

HIGH STRENGTH FINE GRAINED STRUCTURAL STEEL DILLIMAX 890 is a high strength quenched and tempered, fine grained structural steel with a minimum yield strength of 890 N/mm² in its delivered condition (referring to the lowest thickness range), whose mechanical properties are achieved by water quenching followed by tempering. DILLIMAX 890 fulfils the requirements of EN 10 137. It is preferentia

Copyright ©2018 Sedative Dosing Pdf